What is PrimBio?
Established in 2011, PrimBio has carved out a specialized niche in the biotechnology sector, primarily through its high-throughput RT-PCR testing capabilities and advanced genomic innovation. The company serves a diverse clientele, ranging from individual travelers requiring rapid COVID-19 results to clinicians and researchers seeking sophisticated cancer diagnostics. By integrating high-quality laboratory services with rapid turnaround times, PrimBio has become a critical partner for health authorities and private healthcare providers alike. Their operational model emphasizes the intersection of personalized medicine and scalable clinical testing, ensuring that diagnostic precision remains accessible for both routine screening and complex genomic sequencing initiatives.
How much funding has PrimBio raised?
PrimBio has raised a total of $89K across 1 funding round:
Debt
$89K
Debt (2021): $89K with participation from PPP
Key Investors in PrimBio
PPP
Public-Private Partnership
What's next for PrimBio?
With this latest infusion of capital, PrimBio is poised to accelerate its strategic roadmap, focusing on the expansion of its clinical testing infrastructure and the deepening of its genomic research capabilities. The company is expected to leverage these resources to enhance its diagnostic throughput, potentially broadening its portfolio of cancer diagnostics and personalized medicine offerings. As the healthcare sector continues to prioritize rapid, accurate, and data-driven diagnostic solutions, PrimBio's focus on technological agility and collaborative health initiatives positions it to capture further market share. Future growth will likely center on scaling laboratory capacity and strengthening partnerships with clinical institutions to solidify its role as a leader in the diagnostic services market.
See full PrimBio company page
